LAVA Therapeutics N.V.
Company Management

LAVA Therapeutics N.V.

Biotechnology Research United States 36 employees
Employees
36
Contacts
3
Emails
3
Phones
2

LAVA Therapeutics N.V. Overview

Headquarters
United States
Phone Number
Available in AeroLeads
Industry
Biotechnology Research
Employees
36
Founded
2016
Funding
83.0M
Company Email
Available in AeroLeads
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)

About LAVA Therapeutics N.V.

At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T-cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T-cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune system. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we are the only company developing bispecific gamma-delta T-cell engaging antibodies for the treatment of cancer. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor specific antigen CD1d, which can be overexpressed in multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), among other tumor types. LAVA-051 will enter a Phase I/IIa study in 1Q21.

LAVA Therapeutics N.V. Contact Details

People in AeroLeads
4
With contact data
3
Email contacts
3
75.0% coverage
Phone contacts
2
50.0% coverage

LAVA Therapeutics N.V. Org Chart

Sample employees and titles
Name Title Contact
Peter Ros Vice President Finance & Operations - Finance & Accounting Professional - Non-executive Board Member - Associate at Imra Netwerk
Email
Fred M. Powell Pharmaceutical Executive
Email Phone
Stephen Hurly CEO, President, Director at Lava Therapeutics
Email Phone
Amy Garabedian Biotech General Counsel - Trusted Legal Partner for Growth-stage & Emerging Biotechs - Transactions - Ip - Strategic Guidance - Governance
View

Employees by Management Level

Individual contributor 5 profiles
Senior / Lead 4 profiles
Executive 3 profiles
Manager 1 profile

Department Contact Coverage

Department Contacts Email Phone
General 8 8 0

Compare Similar Companies to LAVA Therapeutics N.V.